Page 143 - Read Online

Murthy et al. Cancer Drug Resist 2019;2:665-79 I http://dx.doi.org/10.20517/cdr.2019.002 Page 677

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Flohr C, Bürkle A, Radicella JP, Epe B. Poly (ADP-ribosyl) ation accelerates DNA repair in a pathway dependent on Cockayne
syndrome B protein. Nucleic Acids Res 2003;31:5332-37.
2. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly (ADP-ribose) polymerase (PARP) inhibitor lethality in
homologous recombination-deficient cells. Proc Natl Acad Sci U S A 2011;108:3406-11.
3. Couto CA, Wang HY, Green JC, Kiely R, Siddaway R, et al. PARP regulates nonhomologous end joining through retention of Ku at
double-strand breaks. J Cell Biol 2011;194:367-75.
4. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: exploiting the fundamental
vulnerability of ovarian cancer. Cancer Discov 2015;5:1137-54.
5. Sfeir A, Symington LS. Microhomology-mediated end joining: a back-up survival mechanism or dedicated pathway? Trends Biochem
Sci 2015;40:701-14.
6. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly
(ADP-ribose) polymerase. Nature 2005;434:913-7.
7. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic
strategy. Nature 2005;434:917-21.
8. Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose) n participates in DNA excision repair. Nature 1980;283:593-6.
9. Purnell MR, Whish WJ. Novel inhibitors of poly (ADP-ribose) synthetase. Biochem J 1980;185:775-7.
10. Calvert H, Azzariti A. The clinical development of inhibitors of poly (ADP-ribose) polymerase. Ann Oncol 2011;22(suppl_1):i53-9.
11. Calabrese CR, Batey MA, Thomas HD, Durkacz BW, Wang LZ, et al. Identification of potent nontoxic poly (ADP-Ribose)
polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res 2003;9:2711-8.
12. Plummer R1, Jones C, Middleton M, Wilson R, Evans J, et al. Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699,
in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008;14:7917-7923.
13. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO,et al. High sensitivity of BRCA1-deficient mammary tumors to
the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008;105:17079-84.
14. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, et al. Poly (ADP)-ribose polymerase inhibition: frequent durable
responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512-9.
15. Kaye SB, Lubinski J, Matulonis U, Ang JE. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety
of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2
mutations and recurrent ovarian cancer. J Clin Oncol 2011;30:372-9.
16. Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, et al. Efficacy and safety of olaparib monotherapy
in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol
2016;140:199-203.
17. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in
patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. The Lancet 2010;376:245-51.
18. Kaufman B, R Shapira-Frommer, Schmutzler RK, Audeh MW, Friedlander M, et al. Olaparib monotherapy in patients with advanced
cancer and a germline BRCA1/2 mutation. J Clin Oncol 2014;33:244-50.
19. Kristeleit RS, Shapira-Frommer R, Oaknin A, Balmaña J, Ray-Coquard IL,et al. Clinical activity of the poly (ADP-ribose) polymerase
(PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis
of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2). Ann Oncol 2016;27:856O.
20. Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, et al. A phase I-II study of the oral PARP inhibitor rucaparib in patients
with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res 2017;23:4095-106.
21. Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma
(ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 2017;18:75-87.
22. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, et al. Olaparib maintenance therapy in platinum-sensitive relapsed
ovarian cancer. N Engl J Med 2012;366:1382-92.
23. Mirza MR, Monk BJ, Herrstedt J, S DM, Oza AM, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian
cancer. N Engl J Med 2016;375:2154-64.
24. Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oza AM, et al. Rucaparib maintenance treatment for recurrent ovarian
carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet
2017;390:1949-61.
25. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, et al. OCEANS: a randomized, double-blind, placebo-controlled
phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary